Friday 16 October 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.13
0.11
−4.91%
Follow ZNTL
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — |
Altman Z-Score |
— | — | — | — | — | — | — | (2.42) | — |
P/S ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | (4.51) | — | — | — | — | — | (2.09) | — |
P/FCF ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — |
P/Operating CF |
— | (7.70) | — | — | — | — | — | (5.42) | — |
P/B ratio |
— | 0.00 | — | — | — | — | — | 0.64 | — |
Price to Tangible BV |
— | 0.00 | — | — | — | — | — | 0.65 | — |
EV/Sales |
— | 0.00 | — | — | — | — | — | 0.00 | — |
EV/EBITDA |
— | 0.00 | — | — | — | — | — | 0.80 | — |
EV/Operating CF |
— | (1.41) | — | — | — | — | — | 0.91 | — |
EV/FCF |
— | (1.40) | — | — | — | — | — | 0.91 | — |
Quick Ratio |
— | 4.20 | 4.52 | 11.85 | 7.79 | 7.72 | 6.96 | 7.13 | 6.73 |
Current Ratio |
— | 4.30 | 4.62 | 12.07 | 7.98 | 7.98 | 7.16 | 7.32 | 6.93 |
Net Debt/EBITDA |
— | 1.06 | 1.44 | 2.87 | 1.58 | 1.91 | 1.55 | 1.91 | 1.59 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.00 |
Operating CF/Net income |
— | 1.15 | 0.86 | 0.74 | 0.97 | 0.69 | 0.71 | 1.03 | 0.91 |
Capex/Depreciation |
— | 0.00 | (3.17) | (1.06) | (4.21) | 1.11 | 0.05 | 0.05 | (0.34) |
Interest Coverage |
— | (134.03) | — | — | — | — | — | — | — |
| — | 36.59% | 84.29% | (90.61%) | (45.49%) | (59.31%) | (67.06%) | (42.82%) | (49.53%) | |
| — | (102.65%) | (71.06%) | (52.02%) | (38.71%) | (47.66%) | (53.56%) | (33.77%) | (38.11%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (550.27%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (101.63%) | (83.79%) | (37.10%) | (50.39%) | (58.76%) | (67.45%) | (49.06%) | (62.47%) |
Average Days of Receivables |
— | 24,074.24 | 0.00 | 0.00 | 0.00 | — | — | 27.07 | — |
Research and Development Expense of Revenue |
— | 136,125.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 248.82% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 34,708.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 129.20% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.31 | 0.14 | 0.03 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.77% | 0.00% |
Graham Net Nets |
— | (0.85) | — | — | — | — | — | 1.36 | — |
Graham Number |
— | 0.00 | — | — | — | — | — | 0.00 | — |
Earnings Yield |
— | (41.46%) | — | — | — | — | — | (76.57%) | — |
Free Cash Flow Yield |
— | (36.44%) | — | — | — | — | — | (79.40%) | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.95 | 0.00 |
Operating CF per Share |
— | (0.68) | (6.99) | (3.09) | (3.61) | (3.10) | (3.18) | (2.40) | (1.74) |
Capex per Share |
— | 0.00 | (0.06) | (0.03) | (0.14) | (0.05) | (0.01) | 0.00 | 0.01 |
Free Cash Flow per Share |
— | (0.68) | (7.06) | (3.12) | (3.75) | (3.15) | (3.19) | (2.41) | (1.73) |
Cash per Share |
— | 0.70 | 12.01 | 12.04 | 7.96 | 8.27 | 7.38 | 5.22 | 3.42 |
Shareholders Equity per Share |
— | 0.69 | (13.09) | 11.86 | 8.54 | 8.21 | 6.69 | 4.74 | 3.01 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.69 | (13.09) | 11.86 | 8.54 | 8.21 | 6.69 | 4.74 | 3.01 |
Free Cash Flow |
— | (24.25) | (39.49) | (87.58) | (160.20) | (166.30) | (208.40) | (171.02) | (124.55) |
Working Capital |
— | 20.47 | 53.99 | 316.50 | 306.83 | 395.29 | 427.35 | 333.34 | 216.63 |
Capital Expenditures |
— | (0.23) | (0.35) | (0.76) | (6.11) | (2.55) | (0.58) | (0.16) | 0.70 |
Net Current Asset Value |
— | 17.94 | (91.87) | 312.93 | 260.75 | 346.65 | 382.42 | 292.92 | 180.43 |
EV/EBIT |
— | 0.00 | — | — | — | — | — | 0.81 | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | — | — | — | — | — | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.20 | 0.22 | 0.65 | 0.18 | (0.30) | (2.02) | (0.63) | (0.73) |
Cash ROIC |
— | (48.58%) | 654.00% | (13.04%) | (22.74%) | (19.08%) | (22.65%) | (24.15%) | (26.95%) |
Accounts Receivable Turnover |
— | 0.03 | 0.00 | 0.00 | 0.00 | — | — | 17.66 | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.53 | 0.53 | 0.28 | 1.53 | — | — | 3.82 | — |
Average Payables |
— | 3.86 | 3.86 | 6.48 | 10.13 | 11.42 | 13.09 | 11.18 | 7.32 |
Average Assets |
— | 20.52 | 64.26 | 226.52 | 410.03 | 496.91 | 545.50 | 491.01 | 359.65 |
Average Common Equity |
— | (57.58) | (54.17) | 130.05 | 348.93 | 399.25 | 435.71 | 387.29 | 276.70 |
Columns are period end dates